Study Summary
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).
Want to learn more about this trial?
Request More InfoInterventions
AUTO1BIOLOGICAL
Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States |
| Methodist Children's Hospital | San Antonio | Texas | United States |
| Primary Children's Hospital | Salt Lake City | Utah | United States |
| Hospital Vall d'Hebron | Barcelona | Spain | |
| Hospital Nino Jesus | Madrid | Spain | |
| Great Ormond Street Hospital for Children NHS Foundation Trust | London | United Kingdom | |
| Royal Manchester Children's Hospital | Manchester | United Kingdom | |
| Great North Children's Hospital | Newcastle upon Tyne | United Kingdom |